Injective priceINJ

Altseason phases begin with capital rotation into liquid, execution-focused networks. Infrastructure assets with steady usage often act as anchors during expansion cycles. Mid-cap platforms may benefit once large-cap liquidity establishes directional stability. As market structure matures following prolonged consolidation, attention has shifted toward assets capable of absorbing renewed capital inflows without destabilizing price action. Altseason phases are typically characterized by rotation rather than uniform appreciation, with capital flowing first into liquid, infrastructure-focused networks before moving toward higher-beta segments. In this context, market participants are assessing whether leading platforms show signs of balance-sheet repair, liquidity depth, and sustained network activity. The current setup reflects a methodical transition, where expansion potential is tied to execution and usage rather than speculation. Solana (SOL): Throughput as a Liquidity Anchor Solana has re-established itself as a high-throughput network following periods of operational stress and valuation compression. Transaction volume and ecosystem participation have remained visible, supporting liquidity continuity. Analysts tracking SOL describe its role as foundational during rotation phases, where capital seeks scalable execution environments. Price behavior is being evaluated alongside network stability metrics rather than narrative momentum. BNB (BNB): Exchange-Centric Liquidity Stability BNB’s positioning remains closely linked to exchange-based activity and ecosystem utility. Despite broader market volatility, its liquidity profile has remained comparatively stable. Market observers note that BNB often acts as a capital buffer during expansion cycles, benefiting from fee mechanisms and consistent transactional demand. Its performance is frequently measured against ecosystem usage rather than directional speculation. Uniswap (UNI): Protocol Usage as Valuation Input Uniswap continues to function as a central liquidity venue within decentralized markets. After deep drawdowns, UNI’s valuation has been reassessed through protocol fee generation and governance relevance. Observers emphasize that consistent usage across market conditions strengthens its case as a core asset during altseason phases, where decentralized liquidity becomes increasingly active. Injective (INJ): Specialized Infrastructure Gains Attention Injective has been identified as a specialized platform focused on decentralized derivatives and advanced financial primitives. While price volatility has moderated, development activity has remained steady. Market participants tracking INJ focus on whether niche infrastructure can capture sustained demand during broader expansion, positioning it as a mid-cap asset with asymmetric exposure. Sui (SUI): Early-Stage Liquidity Under Rotation Sui represents a newer entrant within the Layer 1 landscape, where valuation remains sensitive to adoption signals. Market analysis centers on whether its architecture can translate technical efficiency into sustained usage. During altseason phases, such assets are often evaluated as rotation targets once large-cap liquidity stabilizes. Tags: Altcoin BNB Crypto market cryptocurrency Solana UNI

In the latest move, asset manager Canary Capital has submitted a filing to the U.S. Securities and Exchange Commission (SEC) to bring a staked Injective ETF to the market. As a result, investors would get a regulated exposure to the INJ INJ $4.74 24h volatility: 5.4% Market cap: $474.29 M Vol. 24h: $60.26 M cryptocurrency along with the option to earn staking rewards. --> Canary Capital Submits S-1 to U.S. SEC for Injective ETF As per the latest regulatory filing, asset manager Canary submitted its S-1 registration statement with the U.S. Securities and Exchange Commission for its proposed staked Injective (INJ) exchange-traded fund. If approved, the Canary Staked Injective ETF would list on Cboe and provide investors with exposure to the spot price of INJ crypto. The ETF will also offer investors the opportunity to earn additional yields through staking rewards. It joins several other crypto ETFs currently awaiting US SEC approval for 2026. The fund structure allows the sponsor to stake all INJ tokens held by the trust through one or more staking providers. However, they haven’t announced any specific staking partners so far. The filing outlines key operational details of the product. U.S. Bancorp Fund Services has been appointed as the transfer agent and cash custodian. At the same time, the BitGo Trust Company will serve as the digital asset custodian. The ETF will track the performance of Injective based on the INJ-USD CCIXber Reference Rate price index. Under the proposed structure, shares of the ETF will be created and redeemed in blocks of 10,000 shares. Canary also disclosed that Paralel Distributors LLC will act as the marketing agent for the product. Growth of the Overall Injective Ecosystem The Injective ecosystem has seen some solid growth in recent years. Transaction activity across the Injective ecosystem has surged sharply over the past three years. In 2023, weekly transaction counts were largely confined to the 0-1,000 range. That figure has since climbed dramatically and is now approaching 1 million transactions per week. GM @injective Ecosystem transaction counts have seen massive growth over the last 3 years. In 2023, this figure was in the 0–1,000 range, while it is now approaching 1M on a weekly basis. This metric shows how much growth the $INJ ecosystem has achieved. It includes not only… pic.twitter.com/m2s6kspJZR — FurkanConsensus.inj 🦇🔊🍉 (@FurkanConsensus) December 18, 2025 The data highlights the expanding usage of the Injective ecosystem beyond basic token transfers. Transaction activity spans decentralized exchanges, minting, staking, derivatives, swaps, NFT interactions, and other on-chain operations The protocol is also catering to key developments in the tokenization of real-world assets. Injective’s Korea Lead, Andrew (@AndKrypto), spoke on Dec. 18 at Hashed’s Open Research Forum, where he outlined how a $10 billion mortgage portfolio from PAPL pineapple is being brought on-chain via Injective. He also discussed Injective’s role in advancing real-world asset (RWA) adoption. This includes exploring new use cases like on-chain trading of pre-IPO stocks. Despite these developments, INJ continues to face selling pressure, with its price correcting nearly 30% over the past month. Will the INJ Price Recover From Here? At the time of writing, INJ’s price is trading 5.6% down at $4.58. On the daily chart, the asset is trading below its 50-day, 100-day, and 200-day moving averages, reflecting continued short-term weakness. At the same time, the Relative Strength Index (RSI) has fallen to 30.67. It shows oversold conditions and hints at a potential for a near-term technical rebound. INJ’s price. | Source TradingView Traders might consider entering near the $4.50 level, with an upside target around $5.50 if prices reclaim key resistance. For a sustained recovery, however, trading volumes need to increase. next Bhushan is a FinTech enthusiast and holds a good flair in understanding financial markets. His interest in economics and finance draw his attention towards the new emerging Blockchain Technology and Cryptocurrency markets. He is continuously in a learning process and keeps himself motivated by sharing his acquired knowledge. In free time he reads thriller fictions novels and sometimes explore his culinary skills. Bhushan Akolkar on X Share:

Canary re-introduces S-1 for ETF Injective with staking. ETF seeks INJ spot price and on-chain yield. BitGo assumes custody and Cboe BZX plans listing. Canary Capital has taken another step in the regulatory process for its Injective ETF by resubmitting its S-1 form to the U.S. Securities and Exchange Commission (SEC). The updated version of the document details the structure of an exchange-traded fund that combines exposure to the spot price of the INJ token with income generation through staking. According to the filing, the primary objective of the ETF is to track the spot price of Injective, while the secondary objective involves delegating the fund's tokens to staking providers to obtain additional yield. The proposal reflects a model that seeks to combine direct exposure to the asset with on-chain strategies, within a regulated traditional market framework. The document indicates that BitGo will be responsible for the custody of the ETF's assets. US Bancorp Fund Services has been designated as administrator, transfer agent, and cash custodian. Although the form confirms that all tokens in the fund can be staked, the specific providers have not yet been disclosed. Related Stories Ripple's XRP spot ETFs approach $1,2 billion, bucking out of BTC/ETH outflows. 16/12/2025 SEC warns of surveillance risks and defends privacy in cryptocurrencies. 15/12/2025 According to the amended S-1 filing, the trust fund will hold Injective tokens and calculate its net asset value based on the CoinDesk Injective USD CCIXber 60m New York Rate benchmark rate. This metric is calculated from a 60-minute weighted average of the INJ-USD price, providing a standardized basis for ETF pricing. Canary Capital also reported that ETF units will be created and redeemed in blocks of 10.000 shares. Parallel Distributors LLC was listed as the marketing agent, while the Cboe BZX Exchange appears as the planned location for listing and trading the product. To date, the issuer has not disclosed the management fee or the trading code for the ETF. Prior to this resubmission, Canary had already registered a statutory trust fund in Delaware as part of the legal structure of the Injective ETF. Market analysts believe that further amendments to the S-1 form may still be filed in the coming weeks, bringing additional adjustments required by the regulatory process. In the market, the Injective token showed a moderate recovery from recent lows, despite a broader selling pressure environment. Derivatives data indicate that total open interest in INJ futures contracts has decreased over the past 24 hours, while short-term positions have slightly increased on some platforms, signaling tactical activity from traders in the short term. Disclaimer: The views and opinions expressed by the author, or anyone mentioned in this article, are for informational purposes only and do not constitute financial, investment or other advice. Investing or trading cryptocurrencies carries a risk of financial loss. Tags: ETF of Injective SEC

Canary refiles S-1 for a staked Injective ETF, detailing custodians, staking plan, and Cboe BZX listing as INJ price and derivatives markets show mixed signals. Summary Canary’s updated S-1 outlines a staked Injective ETF that tracks spot INJ while delegating tokens to staking providers to generate additional yield.​ BitGo is named custodian, U.S. Bancorp Fund Services will administer and handle cash, and the ETF plans 10,000-share creation/redemption blocks on Cboe BZX.​ INJ spot price shows modest recovery from recent lows while overall futures open interest has eased, even as short‑term derivatives activity ticks higher. Canary Capital has filed an amended S-1 registration statement with the U.S. Securities and Exchange Commission for its proposed staked Injective exchange-traded fund, according to regulatory documents. Canary Capital files updated S-1 The updated filing includes details on the price index, custodians, and share distribution plan for the ETF. The trust’s primary investment objective is to provide exposure to the spot Injective price, while the secondary objective is to generate yield through participation in a staking program, according to the SEC submission. BitGo will serve as the custodian of the exchange-traded fund, the filing stated. U.S. Bancorp Fund Services is named as administrator, transfer agent, and cash custodian for the trust. The filing indicated the ETF plans to stake all of the trust’s tokens through one or more staking providers, though specific staking providers were not identified. The issuer has not disclosed the management fee or ticker symbol for the ETF in the current filing. According to the amended S-1, the trust will hold Injective tokens and establish its net asset value with reference to the CoinDesk Injective USD CCIXber 60m New York Rate pricing benchmark. CoinDesk Indices calculates this benchmark based on a 60-minute time-weighted average price of the INJ-USD CCIXber Reference Rate, the filing stated. The issuer will sell or redeem ETF shares in blocks of 10,000, according to the document. The filing also disclosed Paralel Distributors LLC as marketing agent. The ETF plans to list and trade on Cboe BZX Exchange, offering exposure to the spot Injective price along with additional earnings through its staking program. Canary Capital previously registered a statutory trust for the proposed staked Injective ETF in Delaware. Additional S-1 amendments are expected in the coming weeks to reveal further details, according to market observers. The Injective token traded at levels showing a slight recovery from recent lows despite broader market selling pressure, according to market data. Trading volume increased modestly in recent hours. Derivative market data showed total futures open interest for Injective declined over the past 24 hours, while shorter-term futures open interest on several major exchanges increased, according to trading platform data.